Production (Stage)
Akero Therapeutics, Inc.
AKRO
$46.36
-$2.61-5.33%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -70.73M | -70.02M | -72.71M | -55.99M | -53.34M |
| Total Depreciation and Amortization | -- | 15.00K | 1.00K | 1.00K | 1.00K |
| Total Amortization of Deferred Charges | 178.00K | 174.00K | 164.00K | 157.00K | 112.00K |
| Total Other Non-Cash Items | 6.49M | 4.13M | 3.92M | 5.26M | 5.02M |
| Change in Net Operating Assets | -3.61M | -1.39M | -1.80M | -6.88M | 13.08M |
| Cash from Operations | -67.66M | -67.09M | -70.42M | -57.45M | -35.14M |
| Capital Expenditure | -- | 0.00 | 0.00 | -999.00K | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -482.18M | 15.27M | 73.07M | -254.90M | 57.85M |
| Cash from Investing | -482.18M | 15.27M | 73.07M | -255.90M | 57.85M |
| Total Debt Issued | -- | 0.00 | 0.00 | 0.00 | 10.00M |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 396.11M | 76.02M | 3.13M | 327.00K | 357.21M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -576.00K | -29.00K | -64.00K | -477.00K | -274.00K |
| Cash from Financing | 395.53M | 75.99M | 3.07M | -150.00K | 366.94M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -154.32M | 24.17M | 5.71M | -313.50M | 389.65M |